Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$289.40
-1.3%		$255.01
$144.26
▼
$303.30
$14.00B1.4889,576 shs738,886 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
-0.2%		$55.07
$33.76
▼
$59.72
$14.65B0.422.26 million shs1.58 million shs
Icon Plc stock logo
ICLR
Icon
$164.85
+0.8%		$168.05
$66.57
▼
$203.91
$12.52B1.2528,388 shs796,393 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-1.30%-0.82%+11.26%+59.48%+78.74%
Exelixis, Inc. stock logo
EXEL
Exelixis
-0.20%+8.37%+4.07%+11.97%+59.66%
Icon Plc stock logo
ICLR
Icon
+0.78%-3.04%+0.82%+10.30%-8.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$289.40
-1.3%		$255.01
$144.26
▼
$303.30
$14.00B1.4889,576 shs738,886 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
-0.2%		$55.07
$33.76
▼
$59.72
$14.65B0.422.26 million shs1.58 million shs
Icon Plc stock logo
ICLR
Icon
$164.85
+0.8%		$168.05
$66.57
▼
$203.91
$12.52B1.2528,388 shs796,393 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-1.30%-0.82%+11.26%+59.48%+78.74%
Exelixis, Inc. stock logo
EXEL
Exelixis
-0.20%+8.37%+4.07%+11.97%+59.66%
Icon Plc stock logo
ICLR
Icon
+0.78%-3.04%+0.82%+10.30%-8.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.69
Moderate Buy$255.65-11.66% Downside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.07-15.16% Downside
Icon Plc stock logo
ICLR
Icon
2.41
Hold$170.403.37% Upside

Current Analyst Ratings Breakdown

Latest EXEL, CRL, and ICLR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/26/2026
Icon Plc stock logo
ICLR
Icon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/18/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$54.00
8/18/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$54.00
8/11/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B) ➝ Buy (A-)
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$235.00 ➝ $300.00
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$300.00
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$264.00
8/7/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$260.00 ➝ $300.00
8/6/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$291.00
8/6/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$56.00 ➝ $52.00
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.02B3.44$21.66 per share13.36$59.62 per share4.85
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.30$3.02 per share19.53$7.44 per share7.93
Icon Plc stock logo
ICLR
Icon
$8.25B1.53$16.98 per share9.71$122.48 per share1.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-$144.34M-$4.85N/A22.992.88-5.96%15.75%6.51%11/4/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.5615.911.7635.33%42.17%31.76%11/3/2026 (Estimated)
Icon Plc stock logo
ICLR
Icon
$229.34M$4.2638.7015.246.773.99%8.02%4.56%10/28/2026 (Estimated)

Latest EXEL, CRL, and ICLR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.77$3.02+$0.25-$0.03$980.53 million$1.00 billion
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
7/30/2026Q1 2026
Icon Plc stock logo
ICLR
Icon
$2.55$2.56+$0.01$0.94$2.00 billion$2.06 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.92
1.35
1.04
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Icon Plc stock logo
ICLR
Icon
0.23
0.95
0.95

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Icon Plc stock logo
ICLR
Icon
95.61%

Insider Ownership

CompanyInsider Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Icon Plc stock logo
ICLR
Icon
44.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
19,70047.74 million47.12 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Icon Plc stock logo
ICLR
Icon
40,10076.57 million42.88 millionOptionable

Recent News About These Companies

Icon (NASDAQ:ICLR) Stock Sold Rep. Kevin Hern
September 3 at 2:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-icon-nasdaq-iclr-stock-sold-rep-kevin-hern-2026-09-03/
Maple Rock Capital Partners Inc. Acquires 864,300 Shares of Icon Plc $ICLR
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-maple-rock-capital-partners-inc-acquires-864300-shares-of-icon-plc-iclr-2026-09-01/
Wellington Management Group LLP Sells 592,983 Shares of Icon Plc $ICLR
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-sells-592983-shares-of-icon-plc-iclr-2026-08-30/
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?
August 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2981896/icon-plc-iclr-up-2-5-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2981896
Icon Plc (NASDAQ:ICLR) Given Consensus Recommendation of "Hold" by Analysts
August 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30981322
Icon Plc (NASDAQ:ICLR) Given Average Rating of "Hold" by Analysts
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-icon-plc-nasdaq-iclr-given-average-rating-of-hold-by-analysts-2026-08-25/
Icon (NASDAQ:ICLR) Shares Cross Above 200-Day Moving Average - Here's What Happened
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-icon-nasdaq-iclr-shares-cross-above-200-day-moving-average-heres-what-happened-2026-08-25/
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability
August 20, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/20/10433226.htm
A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49
August 19, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9044339/a-look-at-icon-plc-iclr-after-32-gain-gf-value-20822-vs-price-17249
Icon PLC (ICLR) Shares Surge 3.9% -- What GF Score of 93 Tells Investors
August 17, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9039538/icon-plc-iclr-shares-surge-39-what-gf-score-of-93-tells-investors
Firetrail Investments PTY Ltd. Takes Position in Icon Plc $ICLR
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-firetrail-investments-pty-ltd-takes-position-in-icon-plc-iclr-2026-08-17/
194,618 Shares in Icon Plc $ICLR Purchased by Diamond Hill Capital Management LLC Investment Advisor
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-194618-shares-in-icon-plc-iclr-purchased-by-diamond-hill-capital-management-llc-investment-advisor-2026-08-17/
Icon Plc $ICLR Shares Bought by Handelsbanken Fonder AB
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-icon-plc-iclr-shares-bought-by-handelsbanken-fonder-ab-2026-08-14/
Insider Selling: Icon (NASDAQ:ICLR) Director Sells $138,167.89 in Stock
August 13, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-iclr-insider-buying-and-selling-2026-08-13/
Trinity Street Asset Management LLP Raises Stock Position in Icon Plc $ICLR
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-trinity-street-asset-management-llp-raises-stock-position-in-icon-plc-iclr-2026-08-13/
Insider Selling: Icon (NASDAQ:ICLR) Director Sells $138,167.89 in Stock
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-icon-nasdaqiclr-director-sells-13816789-in-stock-2026-08-12/
Icon (NASDAQ:ICLR) Director Sells 841 Shares
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/icon-nasdaqiclr-director-sells-841-shares-2026-08-12/
Icon (NASDAQ:ICLR) Director Sells 2,677 Shares of Stock
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/icon-nasdaqiclr-director-sells-2677-shares-of-stock-2026-08-12/
Linda Grais Sells 841 Shares of Icon (NASDAQ:ICLR) Stock
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/linda-grais-sells-841-shares-of-icon-nasdaqiclr-stock-2026-08-12/
Insider Selling: Icon (NASDAQ:ICLR) Director Sells 841 Shares
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-icon-nasdaqiclr-director-sells-841-shares-2026-08-12/
Icon (NASDAQ:ICLR) CFO Sells 2,267 Shares
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/icon-nasdaqiclr-cfo-sells-2267-shares-2026-08-12/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$289.40 -3.95 (-1.35%)
As of 09/4/2026 03:58 PM Eastern

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$59.01 -0.12 (-0.20%)
As of 09/4/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Icon stock logo

Icon NASDAQ:ICLR

$164.85 +1.27 (+0.78%)
As of 09/4/2026 04:00 PM Eastern

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas